{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T05:45:12Z","timestamp":1782193512786,"version":"3.54.5"},"reference-count":45,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,3,21]],"date-time":"2021-03-21T00:00:00Z","timestamp":1616284800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100013213","name":"Arup Institute for Clinical and Experimental Pathology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013213","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Practical Laboratory Medicine"],"published-print":{"date-parts":[[2021,5]]},"DOI":"10.1016\/j.plabm.2021.e00218","type":"journal-article","created":{"date-parts":[[2021,3,24]],"date-time":"2021-03-24T13:07:46Z","timestamp":1616591266000},"page":"e00218","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["Performance evaluation of five lipoprotein(a) immunoassays on the Roche cobas c501 chemistry analyzer"],"prefix":"10.1016","volume":"25","author":[{"given":"Sara P.","family":"Wyness","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7219-0259","authenticated-orcid":false,"given":"Jonathan R.","family":"Genzen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4932","key":"10.1016\/j.plabm.2021.e00218_bib1","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1126\/science.2530631","article-title":"The mysteries of lipoprotein(a)","volume":"246","author":"Utermann","year":"1989","journal-title":"Science"},{"key":"10.1016\/j.plabm.2021.e00218_bib2","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/0009-3084(94)90119-8","article-title":"Lp(a) lipoprotein: an overview","volume":"67\u201368","author":"Berg","year":"1994","journal-title":"Chem. Phys. Lipids"},{"issue":"Pt 5","key":"10.1016\/j.plabm.2021.e00218_bib3","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1258\/0004563001899799","article-title":"Lipoprotein(a): what\u2019s in a measure?","volume":"37","author":"Wieringa","year":"2000","journal-title":"Ann. Clin. Biochem."},{"issue":"10","key":"10.1016\/j.plabm.2021.e00218_bib4","doi-asserted-by":"crossref","first-page":"3224","DOI":"10.1073\/pnas.84.10.3224","article-title":"Partial amino acid sequence of apolipoprotein(a) shows that it is homologous to plasminogen","volume":"84","author":"Eaton","year":"1987","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"7","key":"10.1016\/j.plabm.2021.e00218_bib5","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/j.jacc.2020.06.040","article-title":"Lipoprotein(a) and family history predict cardiovascular disease risk","volume":"76","author":"Mehta","year":"2020","journal-title":"J.\u00a0Am. Coll. Cardiol."},{"key":"10.1016\/j.plabm.2021.e00218_bib6","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1007\/s40119-020-00177-4","article-title":"Lipoprotein(a) and cardiovascular disease prevention across diverse populations","volume":"9","author":"Pearson","year":"2020","journal-title":"Cardiol. Ther."},{"issue":"6","key":"10.1016\/j.plabm.2021.e00218_bib7","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/j.jacc.2016.11.042","article-title":"A\u00a0test in context: lipoprotein(a): diagnosis, prognosis, controversies, and emerging therapies","volume":"69","author":"Tsimikas","year":"2017","journal-title":"J.\u00a0Am. Coll. Cardiol."},{"key":"10.1016\/j.plabm.2021.e00218_bib8","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.amjcard.2020.03.043","article-title":"Lipoprotein (a): an update on a marker of residual risk and associated clinical manifestations","volume":"126","author":"Shah","year":"2020","journal-title":"Am. J. Cardiol."},{"issue":"1","key":"10.1016\/j.plabm.2021.e00218_bib9","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1172\/JCI115855","article-title":"Apolipoprotein(a) gene accounts for greater than 90% of the variation in plasma lipoprotein(a) concentrations","volume":"90","author":"Boerwinkle","year":"1992","journal-title":"J.\u00a0Clin. Invest."},{"issue":"1","key":"10.1016\/j.plabm.2021.e00218_bib10","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/BF00291233","article-title":"Genetics of the quantitative Lp(a) lipoprotein trait. II. Inheritance of Lp(a) glycoprotein phenotypes","volume":"78","author":"Utermann","year":"1988","journal-title":"Hum. Genet."},{"issue":"1","key":"10.1016\/j.plabm.2021.e00218_bib11","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/BF00291232","article-title":"Genetics of the quantitative Lp(a) lipoprotein trait. I. Relation of LP(a) glycoprotein phenotypes to Lp(a) lipoprotein concentrations in plasma","volume":"78","author":"Utermann","year":"1988","journal-title":"Hum. Genet."},{"issue":"2","key":"10.1016\/j.plabm.2021.e00218_bib12","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1086\/514851","article-title":"The Apo(a) gene is the major determinant of variation in plasma Lp(a) levels in African Americans","volume":"61","author":"Mooser","year":"1997","journal-title":"Am. J. Hum. Genet."},{"issue":"7","key":"10.1016\/j.plabm.2021.e00218_bib13","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1194\/jlr.R051904","article-title":"Lipoprotein (a): impact by ethnicity and environmental and medical conditions","volume":"57","author":"Enkhmaa","year":"2016","journal-title":"J.\u00a0Lipid Res."},{"issue":"7","key":"10.1016\/j.plabm.2021.e00218_bib14","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/S2213-8587(17)30088-8","article-title":"Apolipoprotein(a) isoform size, lipoprotein(a) concentration, and coronary artery disease: a mendelian randomisation analysis","volume":"5","author":"Saleheen","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"4","key":"10.1016\/j.plabm.2021.e00218_bib15","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/BF02592698","article-title":"Lipoprotein(a) immunoassays: comparison of a semi-quantitative latex method and two monoclonal enzyme immunoassays","volume":"25","author":"Marcovina","year":"1995","journal-title":"Int. J. Clin. Lab. Res."},{"issue":"4","key":"10.1016\/j.plabm.2021.e00218_bib16","first-page":"329","article-title":"Measurement of lipoprotein (a): comparison of Macra and Imubind methods","volume":"26","author":"Stroop","year":"1996","journal-title":"Ann. Clin. Lab. Sci."},{"key":"10.1016\/j.plabm.2021.e00218_bib17","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.atherosclerosis.2019.08.015","article-title":"Comparison of lipoprotein (a) serum concentrations measured by six commercially available immunoassays","volume":"289","author":"Scharnagl","year":"2019","journal-title":"Atherosclerosis"},{"issue":"6","key":"10.1016\/j.plabm.2021.e00218_bib18","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/j.clinbiochem.2004.02.001","article-title":"Electrophoretic measurement of lipoprotein(a) cholesterol in plasma with and without ultracentrifugation: comparison with an immunoturbidimetric lipoprotein(a) method","volume":"37","author":"Baudhuin","year":"2004","journal-title":"Clin. Biochem."},{"key":"10.1016\/j.plabm.2021.e00218_bib19","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.cca.2014.10.013","article-title":"Validation of a lipoprotein(a) particle concentration assay by quantitative lipoprotein immunofixation electrophoresis","volume":"439","author":"Guadagno","year":"2015","journal-title":"Clin. Chim. Acta"},{"issue":"10","key":"10.1016\/j.plabm.2021.e00218_bib20","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1515\/CCLM.1999.140","article-title":"International Federation of Clinical Chemistry and Laboratory Medicine (IFCC) standardization project for the measurement of lipoprotein(a). Phase 2: selection and properties of a proposed secondary reference material for lipoprotein(a)","volume":"37","author":"Tate","year":"1999","journal-title":"Clin. Chem. Lab. Med."},{"issue":"8 Pt 1","key":"10.1016\/j.plabm.2021.e00218_bib21","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1093\/clinchem\/44.8.1629","article-title":"International Federation of Clinical Chemistry standardization project for the measurement of lipoprotein(a). Phase I. Evaluation of the analytical performance of lipoprotein(a) assay systems and commercial calibrators","volume":"44","author":"Tate","year":"1998","journal-title":"Clin. Chem."},{"issue":"4","key":"10.1016\/j.plabm.2021.e00218_bib22","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1194\/jlr.R061648","article-title":"Lipoprotein (a) measurements for clinical application","volume":"57","author":"Marcovina","year":"2016","journal-title":"J.\u00a0Lipid Res."},{"issue":"12","key":"10.1016\/j.plabm.2021.e00218_bib23","doi-asserted-by":"crossref","first-page":"1956","DOI":"10.1093\/clinchem\/46.12.1956","article-title":"Use of a reference material proposed by the International Federation of Clinical Chemistry and Laboratory Medicine to evaluate analytical methods for the determination of plasma lipoprotein(a)","volume":"46","author":"Marcovina","year":"2000","journal-title":"Clin. Chem."},{"issue":"5","key":"10.1016\/j.plabm.2021.e00218_bib24","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1016\/j.jacl.2018.07.003","article-title":"Relationship of lipoprotein(a) molar concentrations and mass according to lipoprotein(a) thresholds and apolipoprotein(a) isoform size","volume":"12","author":"Tsimikas","year":"2018","journal-title":"J\u00a0Clin Lipidol"},{"issue":"6","key":"10.1016\/j.plabm.2021.e00218_bib25","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/j.jacl.2014.08.003","article-title":"Lipoprotein(a) mass: a massively misunderstood metric","volume":"8","author":"McConnell","year":"2014","journal-title":"J\u00a0Clin Lipidol"},{"key":"10.1016\/j.plabm.2021.e00218_bib26","unstructured":"Diazyme Lipoprotein (a) Assay Package Insert. 70980 Rev. C. Diazyme Laboratories: Poway, CA."},{"key":"10.1016\/j.plabm.2021.e00218_bib27","unstructured":"K-Assay Lp(a) Package Insert. Rev. 2009-09-16. Kamiya Biomedical: Seattle, WA."},{"key":"10.1016\/j.plabm.2021.e00218_bib28","unstructured":"Pointe Scientific Lipoprotein (a) Assay Package Insert. Rev. 10\/18. MedTest: Canton, MI."},{"issue":"8","key":"10.1016\/j.plabm.2021.e00218_bib30","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/j.jclinepi.2009.02.005","article-title":"A\u00a0review of solutions for diagnostic accuracy studies with an imperfect or missing reference standard","volume":"62","author":"Reitsma","year":"2009","journal-title":"J.\u00a0Clin. Epidemiol."},{"issue":"50","key":"10.1016\/j.plabm.2021.e00218_bib31","doi-asserted-by":"crossref","DOI":"10.3310\/hta11500","article-title":"Evaluation of diagnostic tests when there is no gold standard. A review of methods","volume":"11","author":"Rutjes","year":"2007","journal-title":"Health Technol. Assess."},{"issue":"6","key":"10.1016\/j.plabm.2021.e00218_bib32","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1515\/CCLM.2004.114","article-title":"First WHO\/IFCC international reference reagent for lipoprotein(a) for immunoassay--Lp(a) SRM 2B","volume":"42","author":"Dati","year":"2004","journal-title":"Clin. Chem. Lab. Med."},{"issue":"3","key":"10.1016\/j.plabm.2021.e00218_bib33","first-page":"73","article-title":"Reference materials for the standardization of the apolipoproteins A-1 and B, and lipoprotein(a)","volume":"13","author":"Dati","year":"2001","journal-title":"EJIFCC"},{"issue":"2","key":"10.1016\/j.plabm.2021.e00218_bib34","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1172\/JCI113093","article-title":"Lp(a) glycoprotein phenotypes. Inheritance and relation to Lp(a)-lipoprotein concentrations in plasma","volume":"80","author":"Utermann","year":"1987","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.plabm.2021.e00218_bib35","unstructured":"Lipoprotein(a) (Lp(a)) Package Insert. 06 May 16, Rev. 002. Randox: Crumlin, UK."},{"key":"10.1016\/j.plabm.2021.e00218_bib36","series-title":"Roche Diagnostics International","year":"2019"},{"key":"10.1016\/j.plabm.2021.e00218_bib37","unstructured":"LPA2 Tina-quant Lipoprotein (a) Gen. 2 Package Insert. 2015-01, V 2.0. Roche Diagnostics: Indianapolis, IN."},{"issue":"3","key":"10.1016\/j.plabm.2021.e00218_bib38","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.jacl.2019.04.010","article-title":"Use of Lipoprotein(a) in clinical practice: a biomarker whose time has come. A scientific statement from the National Lipid Association","volume":"13","author":"Wilson","year":"2019","journal-title":"J\u00a0Clin Lipidol"},{"issue":"24","key":"10.1016\/j.plabm.2021.e00218_bib39","doi-asserted-by":"crossref","first-page":"3168","DOI":"10.1016\/j.jacc.2018.11.002","article-title":"AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of blood cholesterol: executive summary: a report of the American College of Cardiology\/American Heart Association task force on clinical practice guidelines","volume":"73","author":"Grundy","year":"2018","journal-title":"J.\u00a0Am. Coll. Cardiol."},{"key":"10.1016\/j.plabm.2021.e00218_bib40","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.atherosclerosis.2020.03.003","article-title":"The dedicated \"Lp(a) clinic\": a concept whose time has arrived?","volume":"300","author":"Tsimikas","year":"2020","journal-title":"Atherosclerosis"},{"issue":"4","key":"10.1016\/j.plabm.2021.e00218_bib41","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1161\/ATVBAHA.114.304785","article-title":"Race is a key variable in assigning lipoprotein(a) cutoff values for coronary heart disease risk assessment: the Multi-Ethnic Study of Atherosclerosis","volume":"35","author":"Guan","year":"2015","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"issue":"2","key":"10.1016\/j.plabm.2021.e00218_bib42","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1002\/clc.22500","article-title":"Lipoprotein(a) and increased cardiovascular risk in women","volume":"39","author":"Costello","year":"2016","journal-title":"Clin. Cardiol."},{"issue":"5","key":"10.1016\/j.plabm.2021.e00218_bib43","doi-asserted-by":"crossref","first-page":"481","DOI":"10.33549\/physiolres.930511","article-title":"Gender differences in plasma levels of lipoprotein (a) in patients with angiographically proven coronary artery disease","volume":"53","author":"Frohlich","year":"2004","journal-title":"Physiol. Res."},{"issue":"3","key":"10.1016\/j.plabm.2021.e00218_bib44","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.jacc.2018.04.060","article-title":"Lipoprotein(a) and cardiovascular risk prediction among women","volume":"72","author":"Cook","year":"2018","journal-title":"J.\u00a0Am. Coll. Cardiol."},{"issue":"2","key":"10.1016\/j.plabm.2021.e00218_bib45","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.jjcc.2012.09.009","article-title":"The current status of lipoprotein (a) in pregnancy: a literature review","volume":"61","author":"Fanshawe","year":"2013","journal-title":"J.\u00a0Cardiol."},{"issue":"2","key":"10.1016\/j.plabm.2021.e00218_bib46","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/j.jvs.2015.08.114","article-title":"Sex and ethnic differences in the associations between lipoprotein(a) and peripheral arterial disease in the Multi-Ethnic Study of Atherosclerosis","volume":"63","author":"Forbang","year":"2016","journal-title":"J.\u00a0Vasc. Surg."}],"container-title":["Practical Laboratory Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352551721000184?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352551721000184?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T01:16:10Z","timestamp":1762478170000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2352551721000184"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5]]},"references-count":45,"alternative-id":["S2352551721000184"],"URL":"https:\/\/doi.org\/10.1016\/j.plabm.2021.e00218","relation":{},"ISSN":["2352-5517"],"issn-type":[{"value":"2352-5517","type":"print"}],"subject":[],"published":{"date-parts":[[2021,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Performance evaluation of five lipoprotein(a) immunoassays on the Roche cobas c501 chemistry analyzer","name":"articletitle","label":"Article Title"},{"value":"Practical Laboratory Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.plabm.2021.e00218","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"e00218"}}